Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dTAGv1 is a heterobifunctional small molecule degrader used in the degradation TAG (dTAG) system to induce the rapid and specific degradation of proteins fused to a mutant FKBP12 (F36V) tag. Developed by the Bradner lab at the Dana-Farber Cancer Institute, dTAGv1 acts as a molecular bridge between the FKBP12(F36V)-tagged target protein and the Cereblon (CRBN) E3 ubiquitin ligase complex, leading to polyubiquitination and subsequent proteasomal degradation of the fusion protein. This system is primarily used as a research tool for functional genomics and target validation, allowing for acute protein depletion to study immediate biological effects, such as identifying transcriptional targets of oncogenic drivers like NSD2 in multiple myeloma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dTAGv1.